(NASDAQ: BIVI) Webinar

Webinar Replay Registration

webinar replay now available.

Date: Monday April 13, 2020 at 4:05 PM EST

Duration: 20+ mins

About BioVie (NASDAQ: BIVI)

BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company's drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.

A live Q&A session, open to current and prospective investors, will immediately follow Chairman & CEO Terren Peizer's presentation.

For more information on BioVie (NASDAQ: BIVI), visit

View investor deck